Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incannex HealthcareIXHL -5.45%32 Market Cap is $35.30 Mil as of Jul. 26, 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Incannex Healthcare ranks worse than 72.85% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Incannex Healthcare's share price for the quarter that ended in Mar. 2026 was $3. Incannex Healthcare's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 13.68 Mil. Therefore, Incannex Healthcare's market cap for the quarter that ended in Mar. 2026 was $41.05 Mil.
Incannex Healthcare's quarterly market cap
declined
from Sep. 2025 ($161.44 Mil) to Dec. 2025 ($128.60 Mil) and
declined
from Dec. 2025 ($128.60 Mil) to Mar. 2026 ($41.05 Mil).
Incannex Healthcare's annual market cap
declined
from Jun. 2023 ($116.49 Mil) to Jun. 2024 ($51.86 Mil) and
declined
from Jun. 2024 ($51.86 Mil) to Jun. 2025 ($41.93 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Incannex Healthcare's Enterprise Value for Today is $-39.04 Mil.
Incannex Healthcare (NAS:IXHL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Incannex Healthcare Market Cap Related Terms
Incannex Healthcare Market Cap Historical Data
* Premium members only.
The historical data trend for Incannex Healthcare's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incannex Healthcare Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Market Cap distribution charts can be found below:
* The bar in red indicates where Incannex Healthcare's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Incannex Healthcare's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incannex Healthcare (IXHL) has a Market Cap of $35.30 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Incannex Healthcare and its competitors. According to the industry distribution chart, Incannex Healthcare ranks #746 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 72.9%.
Is Incannex Healthcare's Market Cap too high?
Incannex Healthcare's current Market Cap is $35.30 Mil. The Drug Manufacturers industry median Market Cap is 208.69. Incannex Healthcare's value of $35.30 Mil is 83.1% below this industry median. Based on the distribution chart, Incannex Healthcare ranks #746 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's Market Cap compare to ETST and SCYX?
According to the Drug Manufacturers industry distribution chart, Incannex Healthcare ranks #746 out of 1024 companies for Market Cap. This places Incannex Healthcare in the lower half of its industry. The industry median Market Cap is 208.69. Incannex Healthcare's value of $35.30 Mil is 83.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 208.69, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incannex Healthcare's current Market Cap of $35.30 Mil is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Incannex Healthcare and its competitors. For the Drug Manufacturers industry, the median Market Cap is 208.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incannex Healthcare's current Market Cap is $35.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current Market Cap of $35.30 Mil. The current Market Cap is $35.30 Mil and 83.1% below the Drug Manufacturers industry median of 208.69. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current Market Cap is $35.30 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score
Get the complete analysis for IXHL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IXHL has been successfully added to your 
